Clinical features of the GIST in this study
| Feature | Total (n=115) | Training set (n=40) | Validation set (n=75) | p Value |
| No of patients (%) | No of patients (%) | No of patients (%) | ||
| Sex | ||||
| Male | 62 (54) | 19 (48) | 43 (57) | 0.314 |
| Female | 53 (46) | 21 (52) | 32 (43) | |
| Age, years | ||||
| <60 | 41 (35) | 19 (48) | 22 (29) | 0.067 |
| ≥60 | 74 (65) | 21 (52) | 53 (71) | |
| Tumour origin | ||||
| Stomach | 66 (57) | 23 (57) | 43 (57) | 0.801 |
| Small intestine | 40 (35) | 15 (38) | 25 (33) | |
| Rectum | 8 (7) | 2 (5) | 6 (8) | |
| Oesophagus | 1 (1) | 0 (0) | 1 (2) | |
| Size, cm* | ||||
| <5 | 46 (41) | 15 (40) | 31 (41) | 0.216 |
| ≥5 | 67 (59) | 23 (60) | 44 (59) | |
| Mitotic index/50 HPF* | ||||
| <5 | 60 (59) | 18 (56) | 42 (60) | 0.139 |
| ≥5 | 42 (41) | 14 (44) | 28 (40) | |
| Classification | ||||
| Small | ||||
| Low risk† | 33 (29) | 9 (23) | 24 (32) | 0.006 |
| Malignant-prone | ||||
| Intermediate risk† | 21 (18) | 9 (23) | 12 (16) | |
| High risk† | 28 (24) | 4 (10) | 24 (32) | |
| Malignant | ||||
| Metastasis | 33 (29) | 18 (44) | 15 (20) | |
↵* Clinical data of some patients were unavailable.
↵† Low risk, size less than 5 cm and mitotic index less than 5/50 high-power fields (HPF); intermediate risk, size less than 5 cm and mitotic index 5–10/50 HPF, or size 5–10 cm and mitotic index less than 5/50 HPF; high risk, size 5–10 cm and mitotic index 5–10/50HPF, or size 10 cm or greater or mitotic index 10/50 HPF or greater.
GIST, gastrointestinal stromal tumour.